A phase II study was undertaken to evaluate the effectiveness of idelalisb plus rituximab in older patients with chronic lymphocytic leukaemia or small lymphocytic leukaemia who were treatment naïve was undertaken. Patients (n = 64) were enrolled in the study. The median age of patients was 71 years. The overall response rate (ORR) was 97% of which 19% were complete responses. In patients with del(17p)/TP53 mutations, the ORR was 100%; it was 97% in those with unmutated IGHV. At 36 months, progression-free survival was 97%.

Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 02/19/19. Copyright © 2018 Lymphoma Coalition. All rights reserved.